Serum Osteocalcin Levels in Children With Nonalcoholic Fatty Liver Disease

Amin, Saleh; Amrousy, Doaa El; Elrifaey, Shaymaa; Gamal, Rasha; Hodeib, Hossam

doi:10.1097/mpg.0000000000001768

Cited by 16 publications

(10 citation statements)

References 34 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with NAFLD exhibited lower serum osteocalcin levels than those in the control group and the osteocalcin concentration were inversely correlated with liver enzymes and the severity of NAFLD. In addition, a serum osteocalcin level below 44.5 ng/ml was revealed to be a good predictor of hepatic steatosis severity with a sensitivity and specificity of 80% (57,58). Furthermore, normoglycemic postmenopausal women with NAFLD exhibited significantly lower serum osteocalcin levels than controls and the serum osteocalcin levels exhibited a negative correlation with the fatty liver index values, even following adjusting for confounding factors (51).…”

Section: Importance Of Biological Experimental Findings Regarding Ostmentioning

confidence: 95%

Osteocalcin‑GPRC6A: An update of its clinical and biological multi‑organic interactions (Review)

2018

View full text Add to dashboard Cite

Osteocalcin is no longer regarded as a molecule exclusive to bone remodeling and osteogenesis, but as a hormone with manifold functions. The discovery of the interaction of osteocalcin with the G protein-coupled receptor family C group 6-member A (GPRC6A) receptor has accompanied the characterization of several roles that this peptide serves in body regulation and homeostasis. These roles include the modulation of memory in the brain, fertility in the testis, fat accumulation in the liver, incretins release in the intestine and adaptation to exercise in muscle, in addition to the well-known effects on β-cell proliferation, insulin release and adiponectin secretion. The aim of the present review was to provide a practical update of the multi-organ effects that osteocalcin exerts through its interaction with GPRC6A and the clinical implications of this.

show abstract

Section: Importance Of Biological Experimental Findings Regarding Ostmentioning

confidence: 95%

Osteocalcin‑GPRC6A: An update of its clinical and biological multi‑organic interactions (Review)

2018

View full text Add to dashboard Cite

show abstract

“… 58 New biomarkers to yield more specific non-invasive diagnosis are constantly arising in different age groups, as seen with the finding of serum osteocalcin levels as important marker of MAFLD progression in children with obesity. 59 Even though novel biomarkers could lead in the future for universal screening methods for MAFLD, the most important tests that should be carried out in high-risk patients include periodic liver function tests (LFTs), given that MAFLD is the main reason for unexpectedly elevated liver enzymes in developed countries, 35 as well as total cholesterol and triglyceride levels, as well as HbA1C monitoring. Screening for metabolic diseases should unquestionably lead to simultaneous screening of MAFLD, and vice versa.…”

Section: How: Steps Towards Appropriate Screening In At-risk Populationmentioning

confidence: 99%

Screening for MAFLD: who, when and how?

Pal

Méndez-Sánchez

2023

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Metabolic-associated fatty liver disease (MAFLD) is a highly prevalent disease with increasing prevalence worldwide. Currently, no universal screening methods have been standardized, even when this disease poses a major health burden. MAFLD as a spectrum of diseases can range from simple steatosis, and steatohepatitis to fibrosis and hepatocellular carcinoma. Its extra-hepatic manifestations are vast and include cardiovascular diseases, extra-hepatic malignancies, cognitive and respiratory alterations. Given its extensive damage targets as well as its high prevalence, timely identification of the high-risk population presenting metabolic dysfunction should undergo universal non-invasive screening methods, which can be carried out through blood tests, easy and effective imaging techniques, such as ultrasound, score calculation and general clinical information brought together from primary patient–physician contact.

show abstract

“…Moreover, it could be a useful marker for progression of NAFLD in children with obesity. 95 Most epidemiological studies suggest that a lower OC level is a risk factor for NAFLD. 96 , 97 Because it is commonly accepted that reduced OC levels are associated with increased bone loss, it is reasonable to assume that in those with NAFLD, lower OC concentrations, among others, could also be one of the factors that links hepatic steatosis and reduced bone mass.…”

Section: What Are the Links Between Nafld And Decreased Bone Mass?mentioning

confidence: 99%

Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis

Filip¹,

Radzki

Bieńko

2018

CIA

View full text Add to dashboard Cite

Excess fat deposition and insulin resistance are considered the main risk factors for nonalcoholic fatty liver disease (NAFLD), and therefore, not surprisingly, the global prevalence of NAFLD increases in parallel with both obesity and type 2 diabetes. Although deterioration of bone homeostasis in patients with NAFLD is commonly observed, its etiology has not been fully elucidated yet. It was shown in several studies that bone tissue seems to be independently associated with NAFLD. A mechanistic perspective puts the liver at the center of mutual interdependencies obviously involving adipose tissue and muscles and also the bone matrix and bone cells, which are relatively novel. In this review, various pathophysiological mechanisms and possible mediating molecules that may interplay between NAFLD and bone tissue are described. Chronic inflammation, vitamin D3, growth hormone, insulin-like growth factor 1, osteopontin, fetuin-A, irisin, osteocalcin, and osteoprotegerin from osteoblasts have been proposed as mediators of mutual interactions among the skeleton, fatty tissue, and liver. Although to date there are still many issues that have not been elucidated, growing evidence suggests that screening and surveillance of bone mineral density in patients with NAFLD should be considered in future strategies and guidelines for NAFLD management.

show abstract

Serum Osteocalcin Levels in Children With Nonalcoholic Fatty Liver Disease

Abstract: Osteocalcin plays an important role in glucose and lipid metabolism for protection against NAFLD occurrence and progression. Moreover, it could be a useful marker for progression of NAFLD in children with obesity.

Cited by 16 publications

References 34 publications

Osteocalcin‑GPRC6A: An update of its clinical and biological multi‑organic interactions (Review)

Osteocalcin‑GPRC6A: An update of its clinical and biological multi‑organic interactions (Review)

Screening for MAFLD: who, when and how?

Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis

Contact Info

Product

Resources

About